Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors

Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic properties, constitutes the only effective first-line drug approved for the treatment of advanced hepatocellular carcinoma (HCC). Despite its capacity to increase survival in HCC patients, its success is quit...

Descripción completa

Detalles Bibliográficos
Autores principales: Méndez-Blanco, Carolina, Fondevila, Flavia, García-Palomo, Andrés, González-Gallego, Javier, Mauriz, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185986/
https://www.ncbi.nlm.nih.gov/pubmed/30315182
http://dx.doi.org/10.1038/s12276-018-0159-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185986/
https://www.ncbi.nlm.nih.gov/pubmed/30315182
http://dx.doi.org/10.1038/s12276-018-0159-1

Ejemplares similares